Lloyd H. Dean
Known title: DirectorCIK: 0001332215
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Progyny (PGNY) shares rise over 6% amid record sales pace. Shares of Progyny jumped about 6% after the company reported a selling season that is pacing toward a record level. Analysts noted the move while also comparing the stock’s valuation to peers such as CRL. The price action comes as the stock trades with an RSI near 61 and holds above a support level around $25.40. The news adds to recent discussion about potential upside, though the stock remains below its 52‑week high.
Transaction History
| SGRY | ▲ Buy | Grant | 11,670 | $160K | 6/5/2026 | View on chart |
| PGNY | ▲ Buy | Grant | 6,792 | $0 | 5/21/2026 | View on chart |
| PGNY | ▲ Buy | Grant | 8,026 | $0 | 5/22/2025 | View on chart |
| PGNY | ▲ Buy | Grant | 5,147 | $0 | 5/23/2024 | View on chart |
| PGNY | ▲ Buy | Grant | 3,654 | $0 | 5/24/2023 | View on chart |
| PGNY | ▲ Buy | Grant | 2,900 | $0 | 10/24/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
SGRY Volumes Soften as Analysts Debate Valuation
Surgery Partners is experiencing lower trading volumes while analysts continue to debate its value. Recent reports note a significant five-year decline, yet some estimates suggest the stock is still below fair value. The company remains a point of interest within the Russell 2000, with mixed views on its competitive position and future challenges.
SGRY Volumes Soften as Analysts Debate Valuation. Surgery Partners is experiencing lower trading volumes while analysts continue to debate its value. Recent reports note a significant five-year decline, yet some estimates suggest the stock is still below fair value. The company remains a point of interest within the Russell 2000, with mixed views on its competitive position and future challenges.